Antithrombin III in fresh frozen plasma, cryoprecipitate, and cryoprecipitate-depleted plasma

Transfusion ◽  
1979 ◽  
Vol 19 (5) ◽  
pp. 597-598 ◽  
Author(s):  
PD Mintz ◽  
PM Blatt ◽  
WJ Kuhns ◽  
HR Roberts
2020 ◽  
Vol 65 (3) ◽  
pp. 351-359
Author(s):  
G. M. Galstyan ◽  
T. V. Gaponova ◽  
F. S. Sherstnev ◽  
A. A. Kupryashov ◽  
N. I. Olovnikova ◽  
...  

Introduction. Cryosupernatant is blood component. Cryosupernatant is the supernatant plasma removed during the preparation of cryoprecipitate. Aim. To provide information on the composition and methods of production, storage, transportation and clinical use of Cryosupernatant. General fi ndings. In comparison with fresh frozen plasma (FFP) and cryoprecipitate, Cryosupernatant plasma is depleted in factor VIII, fi brinogen factor von Willebrand (VWF). Cryosupernatant is defi cient in high molecular weight multimers of VWF, but contains VWF metalloproteinase. The concentrations of factor V, antithrombin III, albumin and immunoglobulins are the same as in FFP and cryoprecipitate. The indications for Cryosupernatant transfusions are massive blood loss in patients with factor VIII inhibitor, plasma exchange in patients with thrombotic thrombocytopenic purpura. For children the doses of Cryosupernatant should be 10-15 mL/kg.


2003 ◽  
Vol 10 (4) ◽  
pp. 64-68
Author(s):  
S T Vetrile ◽  
R G Zakharin' ◽  
A I Bernakevich' ◽  
S A Vasil'ev ◽  
A A Kuleshov ◽  
...  

In 95 patients, operated on for scoliosis, coagulation status was studied using standard tests (activated partial thromboplastin time, prothrombin decrease by Quick, normolized prothrombin ratio, antithrombin III, ethanol and orthophenothroline tests, ХП-a dependent fibrinolysis) pre-, intra- and postoperatively. It was shown that coagulation disturbances developed already during the hemodilution process. Consumption of coagulation factors took place during operation and at early postoperative period. Blood loss by drainage was marked during 48 hours after operation. Maximum changes of coagulation indices were registered on 2-5 day after operation. Use of fresh-frozen plasma, e-aminocaproic acid to decrease of blood grainage loss was grounded.


Circulation ◽  
2018 ◽  
Vol 138 (Suppl_2) ◽  
Author(s):  
Ernesto Lopez ◽  
Zhanglong Peng ◽  
Charles E Wade ◽  
Jessica C Cardenas

Introduction: Endothelial damage and extravasation are deleterious consequences of hemorrhagic shock (HS), associated with inflammation, loss of the endothelial glycocalyx barrier and hyperpermeability. Fresh frozen plasma (FFP) has been shown to preserve the glycocalyx and mitigate endothelial dysfunction following HS, although the mediators of this phenomenon remain unknown. Antithrombin III (ATIII) is a plasma protein with potent anticoagulant and anti-inflammatory activity. ATIII levels are decreased following trauma and particularly in those suffering from HS. Previous work in other disease models has shown that ATIII plays an important role in preserving the endothelial glycocalyx. We hypothesized that following HS, the vascular protective effects of FFP therapy are mediated through ATIII. Methods and Results: In vitro: Confluent endothelial cells were pre-treated with FFP (n=12), ATIII deficient FFP (AT-Def FFP, n=12) or Vehicle (n=12) followed by treatment with TNF-α. The electrical impedance was monitored in real time over 24 H to detect changes in cell-to-cell junctions. We found that FFP treatment prevented the TNF-α -induced endothelial disruption showing a 1.6 and 1.5-fold improvement at 12 and 24 H respectively (vs. Vehicle, p<0.0001). AT-Def FFP showed some protection at 12 H (1.2-fold vs. Vehicle, p=0.05), although it was not maintained at 24 H (0.86-fold vs. Vehicle, p=0.34). In vivo: Under anesthesia , 30 male mice were subjected to a well-described fixed pressure exsanguination model. HS was achieved by sustaining a MAP of 35 mmHg for 90 min followed by resuscitation with either FFP (n=10) or AT-Def FFP (n=10). The expression of the glycocalyx marker, syndecan-1, in lung tissue was measured by immunofluorescence. We found that syndecan-1 expression increased in the FFP treatment group (1.6±0.4, p=0.001) vs. Control (1.0±0.26, n=10). However, these effects were absent in the AT-Def FFP treated group (1.3 ±0.3, p=0.13). Conclusions: These results suggest that ATIII mediates both the protective and reparative effects of FFP. Further studies are needed to elucidate the endothelial intracellular and extracellular signaling pathways mediating the ATIII-induced endothelial barrier preservation.


Author(s):  
R Egbring ◽  
H G Klingemann ◽  
N Heimburger ◽  
H E Karges ◽  
J Beule ◽  
...  

In patients with acute severe hepatic failure the synthesis of clotting factors and inhibitors is considerably diminished. The decrease of clotting factors may be enhanced by liberation of thromboplastic substances from liver cell debris, leading to thrombus formation in the sinusoids and to further cell damage. At the low levels of clotting factors and inhibitors signs of disseminated intravascular coagulation as well as hyperfibrinolysis have been demonstrated. Treatment with heparin to prevent coagulation is insufficient at low levels of antithrombin III (AT III). Therefore, Vogel und Fritsche 1979 suggested the substitution of AT III in these cases.We now report about 3 patients who were admitted to the clinic together with severe signs of liver damage after oral uptake of CCl4 On the day of admission several clotting factors plasminogen and alpha2-antiplasmin were significantly diminished; AT III levels between 25-45% of the norm were found. (Diss. Eckhardt-Klaßnitz). Therefore we started treatment with AT III concentrate from Behringwerke (1000-2000 I.U. daily for 3 to 14 days) and fresh frozen plasma (total volume of 2 1 within the first 3 days).AT III was simultaneously determined by clotting test, a chromogenic substrate test, and immunologically. Hemodialysis was necessary in 2 patients. Unter treatment with AT III and fresh frozen plasma no bleeding tendency occured Though two of the patients showed severe intoxication on admission all could be dismissed with only slight histological signs of liver alterations. Treatment with AT III concentrates, therefore, seems of value in patients with acute yellow liver dystrophy.


2005 ◽  
Vol 5 (04) ◽  
pp. 178-182
Author(s):  
Wieland Kiess ◽  
Manuela Schulz ◽  
Sabine Liebermann ◽  
Roland Pfäffle ◽  
Peter Bührdel ◽  
...  

ZusammenfassungDas Smith-Lemli-Opitz-Syndrom wird durch einen Defekt des letzten Schrittes der Cholesterolbiosynthese, den Mangel an 7-Dehydrocholesterolreduktase, verursacht. Die Akkumulation der Metaboliten 7-Dehydrocholesterol und 8-Dehydrocholesterol, die die wichtigsten biochemischen Marker für die Diagnose der Erkrankung darstellen, sowie der Mangel an Cholesterol können zu multiplen kongenitalen Anomalien führen. Die Ursache des Enzymmangels sind Mutationen innerhalb des DHCR7-Gens, welches auf Chromosom 11q13 lokalisiert ist. Therapeutische Möglichkeiten bestehen in der Gabe von Cholesterol und im Notfall Fresh Frozen Plasma (FFP); der therapeutische Nutzen von Statinen befindet sich zurzeit in der klinischen Erprobung.


Sign in / Sign up

Export Citation Format

Share Document